LabCorp Launches New Neutralizing Antibody Test
June 25 2020 - 1:09PM
Business Wire
Neutralizing Antibody Assay Could Be Used to
Assist in Development of COVID-19 Vaccines and Plasma-Based
Treatments
LabCorp (NYSE: LH), a leading global life sciences company that
is deeply integrated in guiding patient care, today announced the
launch of a new test that can be used to assess the capacity of
antibodies in patient plasma to inhibit the SARS-CoV-2 virus. This
information could be used in the development of COVID-19 vaccines
and the screening of convalescent plasma for prophylactic and
therapeutic use. This neutralizing antibody test will be available
to biopharmaceutical companies, hospitals, blood banks and other
plasma-screening facilities.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20200625005388/en/
Photo courtesy of LabCorp
“By leveraging our drug development and diagnostic capabilities,
we are working tirelessly to find solutions to prevent and treat
COVID-19,” said Paul Kirchgraber, M.D., chief executive officer,
LabCorp’s Drug Development business. “The launch of this
neutralizing antibody assay is the latest effort in our company’s
commitment to accelerate the evaluation of vaccine candidates so
that a successful candidate may reach patients sooner.”
As the research for a safe and effective vaccine continues, some
clinicians are relying on the serum collected from convalescent
patients who had COVID-19 to support treatment of the severely ill.
As research advances, the PhenoSense® assay may be an essential
element in defining the neutralizing antibody activity correlated
with the therapeutic efficacy of convalescent plasma
administration, as well as the relative protective immunity of
vaccine candidates.
“This assay, available only through LabCorp, is based on a
proven and trusted platform developed by our scientists that has
been used for decades in the evaluation of vaccine candidates
designed to prevent other viral infections, including HIV, Ebola
virus, influenza virus, and respiratory syncytial virus (RSV),”
continued Kirchgraber.
For more information, visit:
https://www.covance.com/coronavirus-disease-covid-19/vaccines.html.
About LabCorp
LabCorp (NYSE: LH), an S&P 500 company, is a leading global
life sciences company that is deeply integrated in guiding patient
care, providing comprehensive clinical laboratory and end-to-end
drug development services. With a mission to improve health and
improve lives, LabCorp delivers world-class diagnostics solutions,
brings innovative medicines to patients faster, and uses technology
to improve the delivery of care. LabCorp reported revenue of more
than $11.5 billion in 2019.
To learn more about LabCorp, visit www.LabCorp.com, and to learn
more about LabCorp’s Covance drug development business, visit
www.Covance.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking statements,
including but not limited to statements with respect to clinical
laboratory testing, the potential benefits of COVID-19 serological
testing, our responses to and the expected future impacts of the
COVID-19 pandemic, and the opportunities for future growth. Each of
the forward-looking statements is subject to change based on
various important factors, many of which are beyond the Company’s
control, including without limitation, whether our response to the
COVID-19 pandemic will prove effective, the impact of the COVID-19
pandemic on our business and financial condition, as well as on
general economic, business, and market conditions, competitive
actions and other unforeseen changes and general uncertainties in
the marketplace, changes in government regulations, including
healthcare reform, customer purchasing decisions, including changes
in payer regulations or policies, other adverse actions of
governmental and third-party payers, the Company’s satisfaction of
regulatory and other requirements, patient safety issues, changes
in testing guidelines or recommendations, federal, state, and local
governmental responses to the COVID-19 pandemic, adverse results in
material litigation matters, failure to maintain or develop
customer relationships, our ability to develop or acquire new
products and adapt to technological changes, failure in information
technology, systems or data security, and employee relations. These
factors, in some cases, have affected and in the future (together
with other factors) could affect the Company’s ability to implement
the Company’s business strategy and actual results could differ
materially from those suggested by these forward-looking
statements. As a result, readers are cautioned not to place undue
reliance on any of our forward-looking statements. The Company has
no obligation to provide any updates to these forward-looking
statements even if its expectations change. All forward-looking
statements are expressly qualified in their entirety by this
cautionary statement. Further information on potential factors,
risks and uncertainties that could affect operating and financial
results is included in the Company’s most recent Annual Report on
Form 10-K and subsequent Forms 10-Q, including in each case under
the heading RISK FACTORS, and in the Company’s other filings with
the SEC.
# # #
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200625005388/en/
LabCorp Contacts: Media: Pattie Kushner — 336-436-8263
Media@LabCorp.com Investors: Clarissa Willett — 336-436-5076
Investor@LabCorp.com
Labcorp (NYSE:LH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Labcorp (NYSE:LH)
Historical Stock Chart
From Sep 2023 to Sep 2024